Content area

Abstract

(Endocr Pract. 2017;23:1053-1058) Abbreviations: ATA = American Thyroid Association; BRFS = biochemical recurrence-free survival; CND = central neck dissection; Ct = calcitonin; DFS = disease-free survival; MTC = medullary thyroid carcinoma; OR = odds ratio; OS = overall survival; pCND = prophylactic CND INTRODUCTION Medullary thyroid carcinoma (MTC) is a relatively uncommon tumor that arises from the calcitonin (Ct)-secreting parafollicular C-cells of the thyroid gland (1). Survival endpoints included overall survival (OS), disease-free survival (DFS, defined as no structural evidence of recurrent disease on clinical exam or imaging), and biochemical recurrence-free survival (BRFS). Because this study was performed retrospectively across a large time frame, not all patients were evaluated with the same Ct assay. Logistic regression was used to evaluate the effect of continuous independent variables on binomial dependent variables (i.e., presence of neck metastases as a function tumor size). According to the 2015 ATA recommendations, pCND (level 6) is indicated for all patients, while prophylactic lateral neck dissection can be considered based on pre-operative Ct levels (5).

Details

Title
PROGNOSTIC VARIABLES AFFECTING PRIMARY TREATMENT OUTCOME FOR MEDULLARY THYROID CANCER
Author
Momin, Suhael, MD 1 ; Chute, Deborah, MD 2 ; Burkey, Brian, MD 1 ; Scharpf, Joseph, MD 1 

 Cleveland Clinic Foundation, Head and Neck Institute 
 2Cleveland Clinic Foundation, Pathology and Laboratory Medicine Institute, Cleveland, Ohio. 
Pages
1053-1058
Section
Original Article
Publication year
2017
Publication date
Sep 2017
Publisher
Elsevier Limited
ISSN
1530891X
e-ISSN
19342403
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1941698772
Copyright
Copyright Allen Press Publishing Services Sep 2017